129318-43-0
129318-43-0
Chemical Structure
Alendronate sodium
Synonym(s): Alendronic acid monosodium salt
- CAS No.: 129318-43-0
- Formula:C4H12NNaO7P2
- Molecular Weight:271.08
IUPAC Name: sodium hydrogen (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate
InChIKey: CAKRAHQRJGUPIG-UHFFFAOYSA-M
SMILES: O=P(O)(O)C(CCCN)(O)P(O)(O[Na])=O
Biological Activity: Alendronate sodium is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate sodium induces skeletal alterations in the chicken embryonic development model. Alendronate sodium can be used for osteoporosis research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Alendronate sodium | 98.0% | Alendronate sodium is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate sodium induces skeletal alterations in the chicken embryonic development model. Alendronate sodium can be used for osteoporosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Alendronate-d4 sodium | Alendronate-d4 (sodium) (Alendronic acid-d4 (monosodium salt)) is deuterium labeled Alendronate sodium. Alendronate sodium is an orally active nitrogen-containing bisphosphonate. Alendronate sodium potently inhibits bone resorption. Alendronate sodium is used for the research of postmenopausal osteoporosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Imai K. Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging. 2013;8:681-688. [Content Brief]
- [2]. Sharpe M, et al. Alendronate: an update of its use in osteoporosis. Drugs. 2001;61(7):999-1039. [Content Brief]
- [3]. de Campos WG, et al. Alendronate induces skeletal alterations in the chicken embryonic development model. Toxicol Appl Pharmacol. 2023 Oct 1;476:116673. [Content Brief]
